Boston Scientific Corp (BSX)
54.95
-0.08
(-0.15%)
USD |
NYSE |
Dec 08, 16:00
54.48
-0.47
(-0.86%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 80.50B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 18.63% |
| Valuation | |
| PE Ratio | 67.01 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.812 |
| Price to Book Value | 4.263 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.471 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 43.49% |
Profile
| Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. |
| URL | https://www.bostonscientific.com |
| Investor Relations URL | https://investors.bostonscientific.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 01, 2024 (est.) |
| Last Earnings Release | Oct. 26, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. |
| URL | https://www.bostonscientific.com |
| Investor Relations URL | https://investors.bostonscientific.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | Feb. 01, 2024 (est.) |
| Last Earnings Release | Oct. 26, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |